Medtronic (NYSE:MDT) Sets New 12-Month Low – Here’s What Happened

Shares of Medtronic PLC (NYSE:MDT) hit a new 52-week low during trading on Monday . The company traded as low as $75.60 and last traded at $75.8130, with a volume of 419113 shares traded. The stock had previously closed at $76.15.

Key Headlines Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Investors appear to be reacting favorably to relief from a long-running legal overhang after a False Claims Act case was dismissed, which removes a source of headline risk for Medtronic and could improve sentiment toward the stock. Medtronic shares climb as investors digest legal overhang relief and fresh cardiac-tech updates
• Positive Sentiment: Fresh updates on Medtronic’s cardiac rhythm management and broader device pipeline are reinforcing hopes for stronger product momentum, especially around newer ablation and diabetes-related offerings. Medtronic shares climb as investors digest legal overhang relief and fresh cardiac-tech updates
• Positive Sentiment: Orchestra BioMed said enrollment in the BACKBEAT pivotal trial is on track to finish by the end of Q3 2026, with data expected in Q2 2027 and a planned FDA filing afterward. Because Medtronic is the strategic collaborator, this supports a longer-term growth and pipeline narrative. Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027
• Neutral Sentiment: Medtronic also announced a California site closure as part of restructuring and portfolio consolidation in cardiovascular businesses. That may help efficiency over time, but it is more of an operational cleanup than an immediate stock catalyst. Medtronic to close California site amid restructuring
• Negative Sentiment: Medtronic has still faced recent pressure from broader healthcare-sector rotation and earlier reports of a stock decline, suggesting investors are balancing the positive legal and pipeline news against a still-soft technical backdrop. Medtronic (MDT) Stock Drops Despite Market Gains: Important Facts to Note

Wall Street Analysts Forecast Growth

MDT has been the subject of a number of research reports. Piper Sandler lowered their price objective on Medtronic from $105.00 to $91.00 and set a “neutral” rating for the company in a research report on Wednesday, April 1st. Stifel Nicolaus lowered their price objective on Medtronic from $105.00 to $95.00 and set a “hold” rating for the company in a research report on Monday, April 6th. JPMorgan Chase & Co. lowered their price objective on Medtronic from $105.00 to $100.00 and set a “neutral” rating for the company in a research report on Wednesday, February 18th. Wells Fargo & Company assumed coverage on Medtronic in a research report on Friday, January 30th. They issued an “overweight” rating and a $114.00 price objective for the company. Finally, Robert W. Baird raised their target price on Medtronic from $92.00 to $93.00 and gave the stock a “neutral” rating in a report on Wednesday, April 15th. Fifteen analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $107.80.

Medtronic Stock Performance

The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57. The stock has a market cap of $98.66 billion, a P/E ratio of 21.41, a PEG ratio of 1.77 and a beta of 0.62. The stock has a fifty day simple moving average of $85.98 and a 200-day simple moving average of $94.01.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The firm had revenue of $9.02 billion for the quarter, compared to analysts’ expectations of $8.89 billion. During the same quarter last year, the business earned $1.38 earnings per share. The company’s revenue was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities analysts expect that Medtronic PLC will post 5.57 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, April 17th. Shareholders of record on Friday, March 27th were issued a dividend of $0.71 per share. The ex-dividend date was Friday, March 27th. This represents a $2.84 dividend on an annualized basis and a yield of 3.7%. Medtronic’s dividend payout ratio (DPR) is 79.11%.

Insider Buying and Selling at Medtronic

In other news, EVP Harry Skip Kiil sold 52,524 shares of Medtronic stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the transaction, the executive vice president owned 32,768 shares in the company, valued at $3,201,761.28. The trade was a 61.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.26% of the stock is owned by company insiders.

Hedge Funds Weigh In On Medtronic

Institutional investors have recently modified their holdings of the business. Lodestone Wealth Management LLC acquired a new stake in Medtronic in the 4th quarter valued at approximately $27,000. Anfield Capital Management LLC raised its position in Medtronic by 410.7% in the 4th quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock valued at $27,000 after buying an additional 230 shares during the last quarter. Monetary Solutions Ltd acquired a new stake in Medtronic in the 4th quarter valued at approximately $27,000. Valley Wealth Managers Inc. acquired a new stake in Medtronic in the 3rd quarter valued at approximately $29,000. Finally, Board of the Pension Protection Fund acquired a new stake in Medtronic in the 4th quarter valued at approximately $29,000. Institutional investors own 82.06% of the company’s stock.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).